FDA
-
-
-
-
-
-
-
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
-
-
-
-
-
-
-
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
-
-
-
-
-
-
-
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
-
-
-
-
-
-
-
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
-
-
-
-
-
-
-
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
-
-
-
-
-
-
-
NeoGenomics' (NEO) Inivata Appoints David Eberhard as Chief Medical Officer
-
-
-
-
-
-
-
NeoGenomics (NEO) to Acquire Trapelo Health
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

